If you would like to submit a blog post for consideration, please email firstname.lastname@example.org
Do you see patients with a fear of needles? In this short video, Dr Tony Dicker provides his top three tips for decreasing pain from injections and making procedures more pleasant for your patients. Continue reading “[2 min watch] Top 3 tips for decreasing pain from injections”
In this short video, Dr Tony Dicker offers his top tips for managing common skin cancer surgery complications you might encounter as a GP, primary care or skin cancer doctor. Continue reading “[2 min watch] Tips to manage common skin cancer surgery complications”
This month’s research article is from QIMR Berghofer Medical Research Institute in Brisbane, Australia. The authors consider the important question: what is the risk of melanoma recurrences among patients with a high-risk, localised melanoma? Continue reading “[3 min read] Risk of recurrence in patients with high-risk, localised melanoma”
25 – 28 July 2018 | Brisbane
The 10th Skin Cancer Summit & Masterclasses saw international thought leaders in skin cancer medicine converge in Brisbane to collaborate with GPs from across Australia. The 2018 program once again covered a broad range of topics relevant to doctors working in primary care skin cancer medicine. The Masterclasses focused on core day-to-day material, as a way to reinforce and extend knowledge. The two-day Summit opened up new areas of study, enquiry and interest.
Dermoscopy Masterclass: 25 July 2018
Dr Lallas used the concept of false positive and false negative diagnoses to reinforce our diagnostic accuracy. Clearly, as morphology overlaps the distinction between what is a cancer, and what is not, can provide confusion.
This broad concept was beautifully extended by Prof Marghoob through his presentation on difficult to diagnose melanomas. As we all know, the easy ones are easy. It is the hard-to-diagnose that we risk missing!
The session then moved into important body sites – the face and acral areas, which are important because the morphology of lesions on these sites is different from morphology on other sites. If we don’t understand this and know how the appearances differ, then we can’t accurately recognise cancers.
Our presenters then extended these important concepts to difficult to diagnose non-melanoma skin cancers, as it is not just melanomas that can be tricky. And, as always, we finished with a series of interactive cases.
Surgery Masterclass: 26 July 2018
The second Masterclass covered surgery of the ear. The ear, of course, is a common site for skin cancer because it is so exposed to solar damage. Ear surgery is important because cosmetic results are very visible to the patient and others. So, it is essential to get the surgery right, cure the cancer, and repair the defect as sympathetically as possible.
Dr Con Pappas and Dr Tony Azzi provided a comprehensive overview of how to prepare for and conduct surgery of the ear, across almost all imaginable lesions.
Summit: 27-28 July 2018
The Summit program is deliberately designed to be a mix of very practical, everyday material that supports our daily practice.
This year, key examples of these sessions were those on ‘effectiveness of dermoscopy’, ‘why we miss melanoma’, and ‘radiation oncology’. We also ran sessions that we hope will keep you and your patients safe, including ‘what interests the watchdog’ and ‘monitoring tips and traps’.
We deliberately moved into the future and sought to explore and speculate on what might be. It is clear that artificial intelligence is already with us, and yet most of us don’t really see what is happening and what might be coming. As educated and interested professionals, it is worth being aware of these trends.
We also like to keep you across what is happening outside clinical practice, in areas that are relevant to running your business. So, our sessions on how to run a successful business, and how others organise their own practices, are always very popular.
The Skin Cancer Summit closed with a Gala Dinner at the Queensland Cricketers’ Club. Hosted by the Skin Cancer Institute, the inaugural ‘White Out Skin Cancer’ Gala Dinner donated all proceeds to QIMR Berghofer. The delegates’ generosity and support will make a difference to many lives as we take a step closer to our vision of a world where nobody dies from skin cancer.
Professor Giuseppe Argenziano gives a skin cancer update in which he shares the results of recent research into methotrexate in the treatment of advanced squamous cell carcinoma. Continue reading “Skin Cancer Update with Prof Giuseppe Argenziano [October 2018]”
In this month’s skin cancer update video, Professor Giuseppe Argenziano discusses follow-ups for patients with melanoma. This is important for the early detection of recurrences and second primary melanomas, which are risk factors for patients with a history of melanoma. Continue reading “Skin Cancer Update with Prof Giuseppe Argenziano [September 2018]”
Almost nobody manages to get through life without a scar or two. An examination of most people’s skin will reveal a story of how a scar was obtained. It could be the result of an adventure gone wrong, accident or a medical issue that required surgery. Continue reading “Minimising scarring after BCC removal”
Does ultrasound-based follow-up improve survival outcomes of patients with stage 1-2 melanoma? A study in the European Journal of Cancer compared the efficacy of an ultrasound-based follow-up with a clinical follow-up to determine whether ultrasonography of the regional lymph nodes and abdomen improves melanoma-specific survival.
Different protocols have been used to follow up melanoma patients in stage 1-2 but there is no consensus on the complementary tests that should be requested, or the appropriate intervals between visits. Continue reading “Does ultrasound-based follow-up improve survival of melanoma patients?”
In this month’s skin cancer update video, Associate Professor Giuseppe Argenziano discusses which adjuvant therapies are most effective in the treatment of advanced melanoma.
In stage 3 melanoma patients who have their primary tumour surgically excised, five-year recurrence rates are 70 percent in patients who receive no adjuvant therapy; 64 percent in patients who receive Interferon; 59 percent in patients who receive Ipilimumab; 38 percent in patients who receive Nivolumab; and 37 percent in patients who receive a combination of target therapies. Continue reading “Skin Cancer Update with A/Prof Giuseppe Argenziano [November]”
The US Food and Drug Administration has approved Novartis’ Tafinlar-Mekinist combination for use as a stage 3 melanoma treatment, just four months after the drug was approved for treatment of non-small cell lung cancer with a BRAF V600E mutation.
The BRAF/MEK combination can now be used to treat this particular mutation after studies found that the drug halved patients’ risk of death or melanoma recurrence compared to placebo, in a phase 3 study completed in September. Continue reading “Stage 3 Melanoma Treatment Approved”